Browse Prior Art Database

Crystalline form of SLF Disclosure Number: IPCOM000147748D
Publication Date: 2007-Mar-25
Document File: 2 page(s) / 78K

Publishing Venue

The Prior Art Database

This text was extracted from a PDF file.
At least one non-text object (such as an image or picture) has been suppressed.
This is the abbreviated version, containing approximately 59% of the total text.

Page 1 of 2

Crystalline form of SLF

   (3R)-1-Azabicyclo[2.2.2]oct-3-yl-(1S)-1-phenyl-3,4-dihydroisoquinoline-2-(1H)- carboxylate (1(S)-Phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)- quinuclidinyl ester) is known as SLF. SLF has the molecular formula: C23H26O2, a

molecular weight of 362.4647 and the following chemical structure:



Exact Mass: 362.1994
Mol. Wt.: 362.4647
m/e: 362.1994 (100.0%), 363.2028 (25.6%), 364.2061 (3.1%)

C, 76.21; H, 7.23; N, 7.73; O, 8.83

   SLF succinate is a urinary antispasmodic, acting as a selective antagonist to the M(3)-receptor. It is used for the treatment of symptoms of overactive bladder, such as urinary urgency and increased urinary frequency, as may occur in patients with overactive bladder syndrome ("OAB"). SLF succinate is currently marketed under the tradename VESICARE®. VESICARE® has been approved by the FDA for once daily treatment of OAB and is prescribed as 5 mg and 10 mg tablets.

   Sample of SLF succinate, prepared according to WO 2005/105795, was analyzed by X-Ray Powder diffraction and found to contain crystal Form of SLF. Pattern 1 is the XRD pattern of crystal Form SLF.



[This page contains 1 picture or other non-text object]

Page 2 of 2

SLF RR-713 with spin.raw

   According to pattern 1, the crystalline form of SLF succinate is characterized by X- ray powder diffraction (XRPD) ma...